Category: Healthcare & Pharma / 医药医疗

Healthcare & Pharma / 医药医疗

Pharma opening measures under the 2026 action plan

The 2026 action plan supports rules for drug segmented manufacturing to facilitate overseas marketing-authorisation holders in cross-border segmented production. 2026年行动方案支持出台药品分段生产细则,便利境外药品上市许可持有人开展跨境分段生产。Pilot regions for biotechnology and wholly-foreign-owned hospitals will be...

Healthcare & Pharma / 医药医疗

Healthcare & pharma market access (NMPA)

Market access hinges on NMPA registration, not foreign approval — an FDA/EMA licence does not register a product in China. 市场准入关键在于NMPA注册而非境外批准——FDA或EMA许可并不等于在中国注册。Imported drugs and devices need a registered China...

Load more posts

Top

Search